

# Global Precision Psychiatry Market: Focus on Product Type, Biomarker, Sample, Technology, Applications, End Users, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2026

https://marketpublishers.com/r/G689A97A1F6AEN.html

Date: March 2021

Pages: 279

Price: US\$ 5,000.00 (Single User License)

ID: G689A97A1F6AEN

## **Abstracts**

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at <a href="mailto:order@marketpublishers.com">order@marketpublishers.com</a> with your request.

Market Report Coverage - Precision Psychiatry

Market Segmentation

Product Type- Products and Services

Sample Type – Blood-Based and Non-Blood-Based (Saliva, CSF, Urine, and others)

Biomarker Type – Genetic Biomarker and Protein Biomarker

Technology – Sequencing (NGS and Sanger Sequencing), Polymerase Chain Reaction (RT-PCR and dPCR), Microarray, Immunoassay, Liquid Chromatography-Mass Spectrometry (LC-MS) and Other Technologies

Application – Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Bipolar Disease, and Other Applications

End User – Academic and Research Institutions, Hospitals and Diagnostic



#### Laboratories, and Other End Users

# Regional Segmentation

North America - U.S., and Canada

Europe - Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe

Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest-of-Asia-Pacific

Latin America – Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

#### **Growth Drivers**

**Decreasing Cost of Sequencing** 

Increasing Adoption of Inorganic Growth Strategies

Global Increase in Mental Health Burden

## Market Challenges

Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry

Lack of Awareness for Precision Psychiatry Diagnostics

#### Market Opportunities

Increased Use of Precision Diagnostics for Drug Development by Pharmaceutical and Companion Diagnostics Companies



Massive Scope for Adoption of NGS-Based Genetic Tests in Emerging Markets

## **Key Companies Profiled**

Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, ARUP Laboratories, Invitae Corporation, OPKO Health, Inc., Laboratory Corporation of America Holdings, Centogene N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Konica Minolta, Inc., Fulgent Genetics, PreventionGenetics

Key Questions Answered in this Report:

How is precision psychiatry revolutionizing the field of mental health diagnostics?

What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?

What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?

How is the COVID-19 pandemic impacting the global precision psychiatry landscape?

What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?

What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?

What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?

How is each segment of the market expected to grow during the forecast period from 2021 to 2026, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:

Product Type (Products and Services)



Sample (Blood-Based and Non-Blood-Based)

Biomarker (Genetic Biomarkers and Protein)

Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others)

Application (Parkinson's Disease, Autism, Alzheimer's Disease, Depression, Schizophrenia, Bipolar Disorder, and Others)

End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others)

Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)

What are the growth opportunities for the companies in the region of their operation?

Who are the leading players with significant offerings in the global precision psychiatry market?

Which companies are anticipated to be highly disruptive in the future, and why?

What are the current unmet needs that are being faced in the global precision psychiatry market?

#### Market Overview

Our healthcare experts have found the precision psychiatry market to be one of the most rapidly evolving and dynamic markets, and the global market for precision psychiatry is predicted to grow at a CAGR of 17.26% over the forecast period of 2021-2026. The market is driven by certain factors, which include decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden, that are fuelling the growth of the global precision psychiatry market.



The market is favored by the developments in the field of molecular diagnostics, which are used for the diagnosis and assessment of psychiatric disorders. Currently, the precision psychiatry industry is witnessing an upsurge due to the decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden. Additionally, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis related to the onset and manifestation of psychiatric disorders are some of the critical factors that are expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust precision psychiatry solutions for a wide range of applications to support clinicians in conducting an in-depth molecular analysis.

Within the research report, the market is segmented on the basis of product type, biomarker, sample, technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

## Competitive Landscape

The exponential rise in the number of cases associated with psychiatric disorders has created a buzz among the biotechnology companies to further invest in the development of molecular diagnostics for the assessment of mental disorders, further aiding clinicians to offer precision medicine. Due to the presence of a diverse product portfolio and intense market penetration, Quest Diagnostics Incorporated has been a pioneer in the precision psychiatry ecosystem.

On the basis of region, North America holds the largest share of the precision psychiatry market due to high infusion of funding from the government organizations for conducting research on psychiatric disorders, growing prevalence of mental disorders, growing awareness about precision medicine, and increasing awareness about early detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR of 20.54% during the forecast period, 2021-2026.



## **Contents**

### **Executive Summary**

#### 1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

#### **2 MARKET SCOPE**

- 2.1 Scope of the Study
- 2.2 Key Questions Answered in the Report

#### 3 RESEARCH METHODOLOGY

- 3.1 Global Precision Psychiatry Market: Research Methodology
- 3.2 Data Sources
  - 3.2.1 Primary Data Sources
  - 3.2.2 Secondary Data Sources
- 3.3 Market Estimation Model
- 3.4 Criteria for Company Profiling

#### **4 MARKET OVERVIEW**

- 4.1 Market Definition
- 4.2 Market Footprint and Growth Potential
- 4.3 Future Potential
- 4.4 COVID-19 Impact: Global Precision Psychiatry Market

#### **5 MARKET DYNAMICS**

- 5.1 Overview
- 5.2 Market Drivers
  - 5.2.1 Decreasing Cost of Sequencing
  - 5.2.2 Increasing Adoption of Inorganic Growth Strategies in the Market
  - 5.2.3 Global Increase in Mental Health Burden
- 5.3 Market Restraints
- 5.3.1 Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry



- 5.3.2 Lack of Awareness for Precision Psychiatry Diagnostics
- 5.4 Market Opportunities
  - 5.4.1 Increased Use of Precision Diagnostics for Drug Development by

Pharmaceutical and Companion Diagnostics Companies

5.4.2 Massive Scope for Adoption of NGS-based Genetic Tests in Emerging Markets

#### **6 INDUSTRY INSIGHTS**

- 6.1 Overview
- 6.2 Legal Requirements and Framework in the U.S.
  - 6.2.1 FDA Regulation
  - 6.2.2 CMS Regulation
- 6.3 Legal Requirements and Framework in Europe
- 6.4 Legal Requirements and Framework in Asia-Pacific
  - 6.4.1 China
  - 6.4.2 Japan
  - 6.4.3 South Korea
  - 6.4.4 Australia

#### 7 COMPETITIVE LANDSCAPE

- 7.1 Product Launches
- 7.2 Product Approvals and Designations
- 7.3 Synergistic Activities
- 7.4 Acquisitions
- 7.5 Funding
- 7.6 Market Share Analysis, by Company, 2019–2020
- 7.7 Growth Share Analysis
  - 7.7.1 Growth Share Analysis (by Company)

## **8 GLOBAL PRECISION PSYCHIATRY MARKET (BY PRODUCT TYPE)**

- 8.1 Overview
- 8.2 Products
- 8.3 Services

## 9 GLOBAL PRECISION PSYCHIATRY MARKET (BY BIOMARKER TYPE)

9.1 Overview



#### 9.2 Genetic Biomarkers

- 9.2.1 Genetic Biomarkers (by Application)
  - 9.2.1.1 Parkinson's Disease
  - 9.2.1.2 Autism
  - 9.2.1.3 Alzheimer's Disease
  - 9.2.1.4 Depression
  - 9.2.1.5 Schizophrenia
  - 9.2.1.6 Bipolar Disorder
  - 9.2.1.7 Other Applications
- 9.3 Protein Biomarkers
  - 9.3.1 Protein Biomarkers (by Application)
    - 9.3.1.1 Parkinson's Disease
    - 9.3.1.2 Autism
    - 9.3.1.3 Alzheimer's Disease
    - 9.3.1.4 Depression
    - 9.3.1.5 Schizophrenia
    - 9.3.1.6 Bipolar Disorder
    - 9.3.1.7 Other Applications

## 10 GLOBAL PRECISION PSYCHIATRY MARKET (BY SAMPLE)

- 10.1 Overview
- 10.2 Blood-Based
- 10.3 Non-Blood-Based
  - 10.3.1 Saliva
  - 10.3.2 Urine
  - 10.3.3 Cerebral Spinal Fluid (CSF)
  - 10.3.4 Others

## 11 GLOBAL PRECISION PSYCHIATRY MARKET (BY TECHNOLOGY)

- 11.1 Overview
- 11.2 Sequencing
- 11.2.1 Next-Generation Sequencing (NGS)
- 11.2.2 Sanger Sequencing
- 11.3 Polymerase Chain Reaction (PCR)
  - 11.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)
  - 11.3.2 Digital Polymerase Chain Reaction (dPCR)
- 11.4 Microarray



- 11.5 Immunoassay
- 11.6 Liquid Chromatography-Mass Spectrometry (LC-MS)
- 11.7 Other Technologies

# 12 GLOBAL PRECISION PSYCHIATRY MARKET (BY APPLICATION)

- 12.1 Overview
- 12.2 Alzheimer's Disease
- 12.2.1 Global Precision Psychiatry Market for Alzheimer's Disease (by Technology)
- 12.3 Parkinson's Disease
- 12.3.1 Global Precision Psychiatry Market for Parkinson's Disease (by Technology)
- 12.4 Autism
  - 12.4.1 Global Precision Psychiatry Market for Autism (by Technology)
- 12.5 Depression
  - 12.5.1 Global Precision Psychiatry Market for Depression (by Technology)
- 12.6 Schizophrenia
  - 12.6.1 Global Precision Psychiatry Market for Schizophrenia (by Technology)
- 12.7 Bipolar Disorder
  - 12.7.1 Global Precision Psychiatry Market for Bipolar Disorder (by Technology)
- 12.8 Other Applications

# 13 GLOBAL PRECISION PSYCHIATRY MARKET (BY END USER)

- 13.1 Overview
- 13.2 Hospitals and Diagnostic Laboratories
- 13.3 Academic and Research Institutions
- 13.4 Other End Users

## 14 GLOBAL PRECISION PSYCHIATRY MARKET (BY REGION)

- 14.1 Overview
- 14.2 North America
  - 14.2.1 U.S.
  - 14.2.2 Canada
- 14.3 Europe
  - 14.3.1 Germany
  - 14.3.2 UK.
  - 14.3.3 France
  - 14.3.4 Italy



- 14.3.5 Spain
- 14.3.6 Netherlands
- 14.3.7 Rest-of-Europe
- 14.4 Asia-Pacific
  - 14.4.1 China
  - 14.4.2 Japan
  - 14.4.3 South Korea
  - 14.4.4 Australia
  - 14.4.5 India
  - 14.4.6 Rest-of-Asia-Pacific
- 14.5 Latin America
  - 14.5.1 Brazil
  - 14.5.2 Mexico
  - 14.5.3 Rest-of-Latin America
- 14.6 Rest-of-the-World (RoW)

#### 15 COMPANY PROFILES

- 15.1 Overview
- 15.2 Illumina, Inc.
  - 15.2.1 Company Overview
  - 15.2.2 Role of Illumina, Inc. in the Global Precision Psychiatry Market
  - 15.2.3 Financials
  - 15.2.4 Key Insights About Financial Health of the Company
  - 15.2.5 SWOT Analysis
- 15.3 F. Hoffmann-La Roche Ltd.
  - 15.3.1 Company Overview
  - 15.3.2 Role of F. Hoffmann-La Roche Ltd in the Global Precision Psychiatry Market
  - 15.3.3 Financials
  - 15.3.4 Key Insights About Financial Health of the Company
  - 15.3.5 SWOT Analysis
- 15.4 Bio-Rad Laboratories, Inc.
  - 15.4.1 Company Overview
  - 15.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Precision Psychiatry Market
  - 15.4.3 Financials
  - 15.4.4 Key Insights About Financial Health of the Company
  - 15.4.5 SWOT Analysis
- 15.5 QIAGEN N.V.
- 15.5.1 Company Overview



- 15.5.2 Role of QIAGEN N.V. in the Global Precision Psychiatry Market
- 15.5.3 Financials
- 15.5.4 Key Insights about Financial Health of the Company
- 15.5.5 SWOT Analysis
- 15.6 Quest Diagnostics Incorporated
  - 15.6.1 Company Overview
- 15.6.2 Role of Quest Diagnostics Incorporated in the Global Precision Psychiatry

#### Market

- 15.6.3 Financials
- 15.6.4 SWOT Analysis
- 15.7 ARUP Laboratories
- 15.7.1 Company Overview
- 15.7.2 Role of ARUP Laboratories in the Global Precision Psychiatry Market
- 15.7.3 SWOT Analysis
- 15.8 Invitae Corporation
  - 15.8.1 Company Overview
  - 15.8.2 Role of Invitae Corporation, Inc. in the Global Precision Psychiatry Market
  - 15.8.3 Financials
  - 15.8.4 Key Insights About Financial Health of the Company
  - 15.8.5 SWOT Analysis
- 15.9 OPKO Health, Inc.
  - 15.9.1 Company Overview
  - 15.9.2 Role of OPKO Health, Inc. in the Global Precision Psychiatry Market
  - 15.9.3 Financials
  - 15.9.4 Key Insights About Financial Health of the Company
  - 15.9.5 SWOT Analysis
- 15.1 Laboratory Corporation of America Holdings
  - 15.10.1 Company Overview
  - 15.10.2 Role of Laboratory Corporation of America Holdings in the Global Precision

## **Psychiatry Market**

- 15.10.3 Financials
- 15.10.4 SWOT Analysis
- 15.11 CENTOGENE N.V.
  - 15.11.1 Company Overview
  - 15.11.2 Role of CENTOGENE N.V. in Precision Psychiatry Market
  - 15.11.3 Financials
  - 15.11.4 Key Insights About Financial Health of the Company
  - 15.11.5 SWOT Analysis
- 15.12 Thermo Fisher Scientific Inc.



- 15.12.1 Company Overview
- 15.12.2 Role of Thermo Fisher Scientific Inc. in Global Precision Psychiatry Market
- 15.12.3 Financials
- 15.12.4 Key Insights About Financial Health of the Company
- 15.12.5 SWOT Analysis
- 15.13 Myriad Genetics, Inc.
  - 15.13.1 Company Overview
  - 15.13.2 Role of Myriad Genetics, Inc. in the Global Precision Psychiatry Market
  - 15.13.3 Financials
  - 15.13.4 Key Insights About Financial Health of the Company
  - 15.13.5 SWOT Analysis
- 15.14 Konica Minolta, Inc.
- 15.14.1 Company Overview
- 15.14.2 Role of Konica Minolta, Inc. in the Global Precision Psychiatry Market
- 15.14.3 Financials
- 15.14.4 Key Insights About Financial Health of the Company
- 15.14.5 SWOT Analysis
- 15.15 Fulgent Genetics
  - 15.15.1 Company Overview
  - 15.15.2 Role of Fulgent Genetics in the Global Precision Psychiatry Market
  - 15.15.3 Financials
  - 15.15.4 Key Insights About Financial Health of the Company
  - 15.15.5 SWOT Analysis
- 15.16 PreventionGenetics
  - 15.16.1 Company Overview
  - 15.16.2 Role of the PreventionGenetics in the Global Precision Psychiatry Market
  - 15.16.3 SWOT Analysis



## **List Of Tables**

#### LIST OF TABLES

- Table 8.2: Services Offered by Key Players
- Table 12.1: Precision Psychiatry Products for Alzheimer's Disease
- Table 12.2: Precision Psychiatry Services for Alzheimer's Disease
- Table 12.3: Precision Psychiatry Products for Parkinson's Disease
- Table 12.4: Precision Psychiatry Services for Parkinson's Disease
- Table 12.5: Precision Psychiatry Products for Autism
- Table 12.6: Precision Psychiatry Services for Autism
- Table 12.7: Precision Psychiatry Products for Depression
- Table 12.8: Precision Psychiatry Service for Depression
- Table 12.9: Precision Psychiatry Products for Schizophrenia
- Table 12.10: Precision Psychiatry Services for Schizophrenia
- Table 12.11: Precision Psychiatry Products for Bipolar Disorder
- Table 12.12: Precision Psychiatry Service for Bipolar Disorder
- Table 12.13: Precision Psychiatry Products for Other Applications
- Table 12.14: Precision Psychiatry Service for Other Applications



# **List Of Figures**

#### LIST OF FIGURES

- Figure 1: Global Burden of Prominent Psychiatric Disorders (2014-2019)
- Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Precision Psychiatry Market
- Figure 3: Global Precision Psychiatry Market (by Product Type), \$Million, 2020 Vs. 2026
- Figure 4: Global Precision Psychiatry Market (by Biomarker), \$Million, 2020 Vs. 2026
- Figure 5: Global Precision Psychiatry Market (by Sample), \$Million, 2020 Vs. 2026
- Figure 6: Global Precision Psychiatry Market (by Technology), \$Million, 2020 Vs. 2026
- Figure 7: Global Precision Psychiatry Market (by Application), \$Million, 2020 Vs. 2026
- Figure 8: Global Precision Psychiatry Market (by End User), \$Million, 2020 Vs. 2026
- Figure 9: Global Precision Psychiatry: Market Snapshot
- Figure 2.1: Global Precision Psychiatry Market: Segmentation
- Figure 3.1: Global Precision Psychiatry Market: Methodology
- Figure 3.2: Primary Research Methodology
- Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
- Figure 4.1: Global Precision Psychiatry Market, \$Million, 2020-2026
- Figure 4.2: Global Precision Psychiatry Market: COVID-19 Impact
- Figure 5.1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
- Figure 5.2: Synergistic Activities, FY2017-FY2020
- Figure 5.3: Global Burden of Prominent Psychiatric Disorders (2014-2019)
- Figure 6.1: FDA IVD Classification and Regulatory Process
- Figure 6.2: Key Changes in EU IVD Regulation 2017/746
- Figure 6.3: Europe's IVD Regulatory Approval Process
- Figure 6.4: Medical Device Regulatory Approval Process in China
- Figure 6.5: Medical Device Regulatory Approval Process in South Korea
- Figure 6.6: Classification of IVD Devices
- Figure 6.7: Medical Device (IVDs) Regulatory Approval Process in Australia
- Figure 7.1: Share of Key Developments and Strategies, January 2017–March 2021
- Figure 7.2: Share of Product Launched (by Company), January 2017–March 2021
- Figure 7.3: Share of Product Approvals and Designations (by Company), January 2017-March 2021
- Figure 7.4: Share of Synergistic Activities (by Company), January 2017-March 2021
- Figure 7.5: Share of Acquisitions (by Company), January 2017-March 2021
- Figure 7.6: Share of Funding (by Company), January 2017-March 2021



- Figure 7.7: Market Share Analysis for Global Precision Psychiatry Market, 2019 and 2020
- Figure 7.8: Growth Share Analysis for Global Precision Psychiatry Market (by Company), 2020
- Figure 8.1: Global Precision Psychiatry Market (by Product Type)
- Figure 8.2: Global Precision Psychiatry Market (by Product Type), 2020-2026
- Figure 8.3: Global Precision Psychiatry Market (Product), \$Million, 2020-2026
- Figure 8.4: Global Precision Psychiatry Market (Services), \$Million, 2020-2026
- Figure 9.1: Global Precision Psychiatry Market (by Biomarker Type), \$Million, 2020-2026
- Figure 9.2: Global Precision Psychiatry Market (by Biomarker Type), 2020 and 2026
- Figure 9.3: Global Precision Psychiatry Market (Genetic Biomarkers), \$Million, 2020-2026
- Figure 9.4: Global Precision Psychiatry Market for Genetic Biomarkers (Parkinson's Disease), \$Million, 2020-2026
- Figure 9.5: Global Precision Psychiatry Market for Genetic Biomarkers (Autism), \$Million, 2020-2026
- Figure 9.6: Global Precision Psychiatry Market for Genetic Biomarkers (Alzheimer's Disease), \$Million, 2020-2026
- Figure 9.7: Global Precision Psychiatry Market for Genetic Biomarkers (Depression), \$Million, 2020-2026
- Figure 9.8: Global Precision Psychiatry Market for Genetic Biomarkers (Schizophrenia), \$Million, 2020-2026
- Figure 9.9: Global Precision Psychiatry Market for Genetic Biomarkers (Bipolar Disorder), \$Million, 2020-2026
- Figure 9.10: Global Precision Psychiatry Market for Genetic Biomarkers (Other Applications), \$Million, 2020-2026
- Figure 9.11: Global Precision Psychiatry Market (Protein Biomarkers), \$Million, 2020-2026
- Figure 9.12: Global Precision Psychiatry Market for Protein Biomarkers (Parkinson's Disease), \$Million, 2020-2026
- Figure 9.13: Global Precision Psychiatry Market for Protein Biomarkers (Autism), \$Million, 2020-2026
- Figure 9.14: Global Precision Psychiatry Market for Protein Biomarkers (Alzheimer's Disease), \$Million, 2020-2026
- Figure 9.15: Global Precision Psychiatry Market for Protein Biomarkers (Depression), \$Million, 2020-2026
- Figure 9.16: Global Precision Psychiatry Market for Protein Biomarkers (Schizophrenia), \$Million, 2020-2026



- Figure 9.17: Global Precision Psychiatry Market for Protein Biomarkers (Bipolar Disorder), \$Million, 2020-2026
- Figure 9.18: Global Precision Psychiatry Market for Protein Biomarkers (Other Applications), \$Million, 2020-2026
- Figure 10.1: Global Precision Psychiatry Market (by Sample)
- Figure 10.2: Global Precision Psychiatry Market (by Sample), 2020-2026
- Figure 10.3: Global Precision Psychiatry Market (Blood-Based), \$Million, 2020-2026
- Figure 10.4: Global Precision Psychiatry Market (Non-Blood-Based), \$Million, 2020-2026
- Figure 10.5: Global Precision Psychiatry Market (by Non-Blood-based Samples), \$Million, 2020-2026
- Figure 10.6: Global Precision Psychiatry Market (Saliva), \$Million, 2020-2026
- Figure 10.7: Global Precision Psychiatry Market (Urine), \$Million, 2020-2026
- Figure 10.8: Global Precision Psychiatry Market (CSF), \$Million, 2020-2026
- Figure 10.9: Global Precision Psychiatry Market (Other Samples), \$Million, 2020-2026
- Figure 11.1: Global Precision Psychiatry Market (by Technology)
- Figure 11.2: Global Precision Psychiatry Market (by Technology), 2020-2026
- Figure 11.3: Global Precision Psychiatry Market (by Sequencing), \$Million, 2020-2026
- Figure 11.4: Global Precision Medicine Market (by Sequencing), 2020 and 2026
- Figure 11.5: Global Precision Psychiatry Market (by NGS), \$Million, 2020-2026
- Figure 11.6: Global Precision Psychiatry Market (by Sanger Sequencing), \$Million, 2020-2026
- Figure 11.7: Global Precision Psychiatry Market (by PCR), \$Million, 2020-2026
- Figure 11.8: Global Precision Psychiatry Market (by PCR), 2020 and 2026
- Figure 11.9: Global Precision Psychiatry Market (RT-PCR), \$Million, 2020-2026
- Figure 11.10: Global Precision Psychiatry Market (dPCR), \$Million, 2020-2026
- Figure 11.11: Global Precision Psychiatry Market (Microarray), \$Million, 2020-2026
- Figure 11.12: Global Precision Psychiatry Market (Immunoassay), \$Million, 2020-2026
- Figure 11.13: Global Precision Psychiatry Market (LC-MS), \$Million, 2020-2026
- Figure 11.14: Global Precision Psychiatry Market (Others Technologies), \$Million, 2020-2026
- Figure 12.1: Global Precision Psychiatry Market (by Application)
- Figure 12.2: Global Precision Psychiatry Market (by Application), \$Million, 2020-2026
- Figure 12.3: Global Precision Psychiatry Market (Alzheimer's Disease), \$Million, 2020-2026
- Figure 12.4: Growth-Share Analysis for Global Precision Psychiatry Market for
- Alzheimer's Disease (by Technology), 2020-2026
- Figure 12.5: Global Precision Psychiatry Market (Parkinson's Disease), \$Million, 2020-2026



Figure 12.6: Growth-Share Analysis for Global Precision Psychiatry Market for

Parkinson's Disease (by Technology), 2020-2026

Figure 12.7: Global Precision Psychiatry Market (Autism), \$Million, 2020-2026

Figure 12.8: Growth-Share Analysis for Global Precision Psychiatry Market for Autism (by Technology), 2020-2026

Figure 12.9: Global Precision Psychiatry Market (Depression), \$Million, 2020-2026

Figure 12.10: Growth-Share Analysis for Global Precision Psychiatry Market for

Depression (by Technology), 2020-2026

Figure 12.11: Global Precision Psychiatry Market (Schizophrenia), \$Million, 2020-2026

Figure 12.12: Growth-Share Analysis for Global Precision Psychiatry Market for

Schizophrenia (by Technology), 2020-2026

Figure 12.13: Global Precision Psychiatry Market (Bipolar Disorder), \$Million, 2020-2026

Figure 12.14: Growth-Share Analysis for Global Precision Psychiatry Market for Bipolar Disorder (by Technology), 2020-2026

Figure 12.15: Global Precision Psychiatry Market (Other Applications), \$Million, 2020-2026

Figure 13.1: Global Precision Psychiatry Market (by End User)

Figure 13.2: Global Precision Psychiatry Market (by End User), \$Million, 2020-2026

Figure 13.3: Global Precision Psychiatry Market (Hospitals and Diagnostic

Laboratories), \$Million, 2020-2026

Figure 13.4: Global Precision Psychiatry Market (Academic and Research Institutions), \$Million, 2020-2026

Figure 13.5: Global Precision Psychiatry Market (Other End Users), \$Million, 2020-2026

Figure 14.1: Global Precision Psychiatry Market (by Region), 2020 and 2026

Figure 14.2: Global Precision Psychiatry Market (by Region), \$Million, 2020-2026

Figure 14.3: Global Precision Psychiatry Market (by Region), 2020-2026

Figure 14.4: North America Precision Psychiatry Market, \$Million, 2020-2026

Figure 14.5: North America: Market Dynamics

Figure 14.6: North America Precision Psychiatry Market (by Country), \$Million, 2020-2026

Figure 14.7: U.S. Precision Psychiatry Market, \$Million, 2020-2026

Figure 14.8: Canada Precision Psychiatry Market, \$Million, 2020-2026

Figure 14.9: Europe Precision Psychiatry Market, \$Million, 2020-2026

Figure 14.10: Europe: Market Dynamics

Figure 14.11: Europe Precision Psychiatry Market (by Country), \$Million, 2020-2026

Figure 14.12: Germany Precision Psychiatry Market, \$Million, 2020-2026

Figure 14.13: U.K. Precision Psychiatry Market, \$Million, 2020-2026

Figure 14.14: France Precision Psychiatry Market, \$Million, 2020-2026



- Figure 14.15: Italy Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.16: Spain Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.17: Netherlands Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.18: Rest-of-Europe Market, \$Million, 2020-2026
- Figure 14.19: Asia-Pacific Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.20: APAC: Market Dynamics
- Figure 14.21: APAC Precision Psychiatry Market (by Country), \$Million, 2020-2026
- Figure 14.22: China Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.23: Japan Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.24: South Korea Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.25: Australia Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.26: India Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.27: RoAPAC Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.28: Latin America Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.29: Latin America: Market Dynamics
- Figure 14.30: Latin America Precision Psychiatry Market (by Country), \$Million,
- 2020-2026
- Figure 14.31: Brazil Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.32: Mexico Precision Psychiatry Market, \$Million, 2020-2026
- Figure 14.33: Rest-of-Latin America Precision psychiatry Market, \$Million, 2020-2026
- Figure 14.34: RoW Precision Psychiatry Market, \$Million, 2021-2026
- Figure 15.1: Total Number of Companies Profiled
- Figure 15.2: Illumina, Inc.: Product Portfolio
- Figure 15.3: Illumina, Inc.: Overall Financials, 2018-2020
- Figure 15.4: Illumina, Inc.: Revenue (by Segment), 2018-2020
- Figure 15.5: Illumina, Inc.: Revenue (by Region), 2018-2020
- Figure 15.6: Illumina, Inc.: R&D Expenditure, 2018-2020
- Figure 15.7: Illumina, Inc.: SWOT Analysis
- Figure 15.8: F. Hoffmann-La Roche Ltd: Portfolio
- Figure 15.9: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
- Figure 15.10: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020
- Figure 15.11: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020
- Figure 15.12: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
- Figure 15.13: F. Hoffmann-La Roche: SWOT Analysis
- Figure 15.14: Bio-Rad Laboratories, Inc.: Portfolio
- Figure 15.15: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
- Figure 15.16: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
- Figure 15.17: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
- Figure 15.18: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020



Figure 15.19: Bio-Rad Laboratories, Inc.: SWOT Analysis

Figure 15.20: QIAGEN N.V.: Portfolio

Figure 15.21: QIAGEN N.V.: Overall Financials, 2018-2020

Figure 15.22: QIAGEN N.V.: Revenue (by Segment), 2018-2020

Figure 15.23: QIAGEN N.V.: Revenue (by Region), 2018-2020

Figure 15.24: QIAGEN N.V.: R&D Expenditure, 2018-2020

Figure 15.25: QIAGEN N.V.: SWOT Analysis

Figure 15.26: Quest Diagnostics Incorporated: Portfolio

Figure 15.27: Quest Diagnostics Incorporated: Overall Financials, 2018-2020

Figure 15.28: Quest Diagnostics Incorporated: Revenue (by Business Segment),

2018-2020

Figure 15.29: Quest Diagnostics Incorporated: SWOT Analysis

Figure 15.30: ARUP Laboratories: Portfolio

Figure 15.31: ARUP Laboratories: SWOT Analysis

Figure 15.32: Invitae Corporation: Portfolio

Figure 15.33: Invitae Corporation: Overall Financials, 2018-2020

Figure 15.34: Invitae Corporation: Revenue (by Segment), 2018-2020

Figure 15.35: Invitae Corporation: Revenue (by Geography), 2018-2020

Figure 15.36: Invitae Corporation: R&D Expenditure, 2018-2020

Figure 15.37: Invitae Corporation: SWOT Analysis

Figure 15.38: OPKO Health, Inc.: Portfolio

Figure 15.39: OPKO Health, Inc.: Overall Financials, 2018-2020

Figure 15.40: OPKO Health, Inc.: Revenue (by Segment), 2018-2020

Figure 15.41: OPKO Health, Inc.: Revenue (by Region), 2018-2020

Figure 15.42: OPKO Health, Inc.: R&D Expenditure, 2018-2020

Figure 15.43: OPKO Health, Inc.: SWOT Analysis

Figure 15.44: Laboratory Corporation of America Holdings: Portfolio

Figure 15.45: Laboratory Corporation of America Holdings: Overall Financials,

2018-2020

Figure 15.46: Laboratory Corporation of America Holdings: Revenue (by Segment),

2018-2020

Figure 15.47: Laboratory Corporation of America Holdings: Revenue (by Region), 2019

Figure 15.48: Laboratory Corporation of America Holdings: SWOT Analysis

Figure 15.49: CENTOGENE N.V.: Overall Product Portfolio

Figure 15.50: CENTOGENE N.V.: Overall Financials, 2017-2019

Figure 15.51: CENTOGENE N.V.: Revenue (by Segment), 2017-2019

Figure 15.52: CENTOGENE N.V.: Sales (by Region), 2017-2019

Figure 15.53: CENTOGENE N.V.: R&D Expenditure, 2017-2019

Figure 15.54: CENTOGENE N.V.: SWOT Analysis



Figure 15.55: Thermo Fisher Scientific, Inc.: Product Portfolio

Figure 15.56: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020

Figure 15.57: Thermo Fisher Scientific Inc.: Revenue (by Business Segment),

2018-2020

Figure 15.58: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020

Figure 15.59: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020

Figure 15.60: Thermo Fisher Scientific Inc.: SWOT Analysis

Figure 15.61: Myriad Genetics, Inc.: Product Portfolio

Figure 15.62: Myriad Genetics, Inc.: Overall Financials, 2018-2020

Figure 15.63: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020

Figure 15.64: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020

Figure 15.65: Myriad Genetics, Inc.: SWOT Analysis

Figure 15.66: Konica Minolta, Inc: Product portfolio

Figure 15.67: Konica Minolta, Inc.: Overall Financials, 2017-2019

Figure 15.68: Konica Minolta, Inc.: Revenue (by Business Segment), 2017-2019

Figure 15.69: Konica Minolta, Inc.: Regional revenue, 2017-2019

Figure 15.70: Konica Minolta, Inc.: R&D Expenditure, 2017-2019

Figure 15.71: Konica Minolta, Inc: SWOT Analysis

Figure 15.72: Fulgent Genetics: Product Portfolio

Figure 15.73: Fulgent Genetics: Overall Financials, 2018-2020

Figure 15.74: Fulgent Genetics: Revenue (by Business Segment), 2018-2020

Figure 15.75: Fulgent Genetics: Revenue (by Region), 2018-2020

Figure 15.76: Fulgent Genetics: R&D Expenditure, 2018-2020

Figure 15.77: Fulgent Genetics: SWOT Analysis

Figure 15.78: PreventionGenetics: Product portfolio

Figure 15.79: PreventionGenetics: SWOT Analysis



#### I would like to order

Product name: Global Precision Psychiatry Market: Focus on Product Type, Biomarker, Sample,

Technology, Applications, End Users, Country Data (15 Countries), and Competitive

Landscape - Analysis and Forecast, 2021-2026

Product link: https://marketpublishers.com/r/G689A97A1F6AEN.html

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/G689A97A1F6AEN.html">https://marketpublishers.com/r/G689A97A1F6AEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970